

Substitute for form 1449/PTO

TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	09/921,143
Filing Date	August 3, 2001
First Named Inventor	Timothy A. COLEMAN
Art Unit	1636
Examiner Name	QIAN, Celine X.

Sheet	1	of	2
-------	---	----	---

Attorney Docket Number	1488.100000N/PAJ/PAC
------------------------	----------------------

U.S. PATENT DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (If Known)			
CQ	US10	6,297,238	10/02/2001	Doyle <i>et al.</i>	
	US11	6,515,105	02/04/2003	Alitalo <i>et al.</i>	
	US12	6,660,744	12/09/2003	Hirst <i>et al.</i>	
	US13	6,713,474	03/30/2004	Hirst <i>et al.</i>	
	US14	6,764,820	07/20/2004	Ferrell <i>et al.</i>	
	US15	6,824,777	11/30/2004	Alitalo <i>et al.</i>	
	US16	2002/0013261 A1	01/31/2002	Pawliuk <i>et al.</i>	
	US17	2002/0019350 A1	02/14/2002	Levine <i>et al.</i>	
	US18	2002/0034501 A1	03/21/2002	Pawliuk <i>et al.</i>	
	US19	2002/0086004 A1	07/04/2002	Adnot <i>et al.</i>	
	US20	2002/0111362 A1	08/15/2002	Rubinfeld, Joseph	
	US21	2002/0151489 A1	10/17/2002	Gravereaux <i>et al.</i>	
	US22	2002/0155421 A1	10/24/2002	Kearney <i>et al.</i>	
	US23	2002/0156081 A1	10/24/2002	Hirst <i>et al.</i>	
	US24	2003/0103943 A1	06/05/2003	Rosengart <i>et al.</i>	
	US25	2003/0125523 A1	07/03/2003	Alitalo <i>et al.</i>	
	US26	2003/0153752 A1	08/14/2003	Hirst <i>et al.</i>	
	US27	2003/0165464 A1	09/04/2003	Enholm <i>et al.</i>	
	US28	2003/0180286 A1	09/25/2003	Carmeliet <i>et al.</i>	
	US29	2003/0187001 A1	10/02/2003	Calderwood <i>et al.</i>	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
		Country Code ² Number ³ Kind Code ⁴ (if known)			
CQ	FP13	WO 00/21560 A1	04/20/2000	Ludwig Institute for Cancer Research; Helsinki University Licensing Ltd. OY	
↓	FP14	WO 00/24412 A2	05/04/2000	Ludwig Institute for Cancer Research; Helsinki University Licensing Ltd. OY	
	FP15	WO 00/58511 A1	10/05/2000	Ludwig Institute for Cancer Research; Helsinki University Licensing Ltd. OY; University of Pittsburgh of the Commonwealth System of Higher Education	
	FP16	WO 00/61186 A1	10/19/2000	Weichselbaum, Ralph R.	
	FP17	WO 00/62798 A2	10/26/2000	St. Elizabeth's Medical Center, Inc.	
	FP18	WO 01/52904 A2	07/26/2001	Gill, Parkash S.	

576305.1

Examiner Signature	/Celine Qian/	Date Considered	
-----------------------	---------------	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Equivalent of Form PTO/SB/08A (07-05)

Approved for use through 07/31/2006

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Complete if Known

Application Number	09/921,143
Filing Date	August 3, 2001
First Named Inventor	Timothy A. COLEMAN
Art Unit	1636
Examiner Name	QIAN, Celine X.
Attorney Docket Number	1488.100000N/PAJ/PAC

Sheet	2	of	2
-------	---	----	---

U.S. PATENT DOCUMENTS

CQ



FOREIGN PATENT DOCUMENTS

T

576305.1

Digitally signed by Celine Qian
DN: cn=Celine Qian, c=US, o=USPTO,
ou=1838, email=celine.qian@uspto.gov
Date: 2008.11.22 17:44:41 -0500

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 601.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

NINTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	09/921,143
Filing Date	August 3, 2001
First Named Inventor	Coleman, Timothy A.
Art Unit	1636
Examiner Name	Qian, Celine X.
Attorney Docket Number	1488.100000N/HCC/PAC

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CQ	US1	5,652,225	07/29/1997	Isner	
	US2	5,661,133	08/26/1997	Leiden and Barr	
	US3	5,693,622	12/02/1997	Wolff <i>et al.</i>	
	US4	5,792,453	08/11/1998	Hammond <i>et al.</i>	
	US5	6,121,246	09/19/2000	Isner	
	US6	6,361,946 B1	03/26/2002	Alitalo and Joukov	
	US7	6,451,764 B1	09/17/2002	Lee and Wood	
	US8	6,645,933 B1	11/11/2003	Alitalo and Joukov	
	US9	2006/0014252 A1	01/19/2006	Lyman	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
CQ	FP1	EP 0 186 084 A2	07/02/1986	Merck & Co. Inc.		
	FP2	JP 64-38100 A	02/08/1989	Toray Ind. Inc.		
	FP3	JP 2-117698 A	05/02/1990	Ajinomoto KK and Toray Ind. Inc.		
	FP4	EP 0 399 816 A1	11/28/1990	Merck & Co. Inc.		
	FP5	WO 94/11506 A1	05/26/1994	Arch Development Corporation		
	FP6	WO 97/17442 A1	05/15/1997	Immunex Corporation		
	FP7	WO 00/45835 A1	08/10/2000	Human Genome Sciences, Inc. and Rosen <i>et al.</i>		
	FP8	WO 02/11769 A1	02/14/2002	Human Genome Sciences, Inc. and Coleman		
	FP9	WO 02/083704 A1	10/24/2002	Human Genome Sciences, Inc. and Rosen <i>et al.</i>		

Examiner Signature	/Celine Qian/	Date Considered	
--------------------	---------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. *Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Application Number	09/921,143
Filing Date	August 3, 2001
First Named Inventor	Coleman, Timothy A.
Art Unit	1636
Examiner Name	Qian, Celine X.
Attorney Docket Number	1488.100000N/HCC/PAC

[illegible]

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ² Number ³ Kind Code ⁴ (if known)				
CQ	FP10	WO 02/083849 A2	10/24/2002	Human Genome Sciences, Inc. and Rosen <i>et al.</i>		
↓	FP11	WO 02/083850 A2	10/24/2002	Human Genome Sciences, Inc. and Rosen <i>et al.</i>		
	FP12	WO 03/097660 A1	11/27/2003	Human Genome Sciences, Inc. and Rosen <i>et al.</i>		

Examiner Signature	/Celine Qian/	Date Considered	
-----------------------	---------------	--------------------	--

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
NINTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/921,143
		Filing Date	August 3, 2001
		First Named Inventor	Coleman, Timothy A.
		Art Unit	1636
		Examiner Name	Qian, Celine X.
Sheet	1 of 5	Attorney Docket Number	1488.100000N/HCC/PAC

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
CQ	NPL1	Danis, R.P., <i>et al.</i> , "Anti-angiogenic therapy of proliferative diabetic retinopathy," <i>Exp. Opin. Pharma.</i> 2:395-407, Ashley Publications Ltd. (March 2001)	
	NPL2	Enholm, B., <i>et al.</i> , "Vascular Endothelial Growth Factor-C: A Growth Factor for Lymphatic and Blood," <i>Trends Cardiovascular Med.</i> 8:292-297, Elsevier Science, Inc. (October 1998)	
	NPL3	Ferrara, N., "Vascular Endothelial Growth Factor and the Regulation of angiogenesis," <i>Recent Prog. Hormone Res.</i> 55:15-36, The Endocrine Society (March 2000)	
	NPL4	Halin, C. and Neri, D., "Antibody-Based Targeting of Angiogenesis," <i>Crit. Rev. Ther. Drug Carrier Syst.</i> 18:299-339, Begell House, Inc. (August 2001)	
	NPL5	Longo, R., <i>et al.</i> , "Anti-angiogenic therapy: Rationale, challenges and clinical studies," <i>Angiogenesis</i> 5:237-256, Kluwer Academic Publishers (December 2002)	
	NPL6	Schlaeppli, J.-M., <i>et al.</i> , "Characterization of a new potent, in vivo neutralizing monoclonal antibody to human vascular endothelial growth factor," <i>J. Cancer Res. Clin. Oncol.</i> 125:336-342, Springer-Verlag (May 1999)	
	NPL7	van der Flier, M., <i>et al.</i> , "Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis," <i>J. Neuroimmunol.</i> 160:170-177, Elsevier B.V. (March 2005)	
	NPL8	Walsh, D.A., "Angiogenesis and arthritis," <i>Rheumatology</i> 38:103-112, British Society for Rheumatology (February 1999)	
	NPL9	Winkler, K., <i>et al.</i> , "Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody," <i>J. Immunol.</i> 165:4505-4514, The American Association of Immunologists (October 2000)	
▼	NPL10	NCBI Entrez, GenBank Report, Accession No. AF010302, Mandriota S.J. and Pepper, M.S., Entry date July 1997	

Examiner Signature	/Celine Qian/	Date Considered	
--------------------	---------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
NINTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/921,143		
		Filing Date	August 3, 2001		
		First Named Inventor	Coleman, Timothy A.		
		Art Unit	1636		
		Examiner Name	Qian, Celine X.		
Sheet	2	of	5	Attorney Docket Number	1488.100000N/HCC/PAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
CQ	NPL11	Anderson, W.F., "Human gene therapy," <i>Nature</i> 392:25-30, Macmillan Magazines Ltd. (April 1998)	
	NPL12	Borg, J.-P., <i>et al.</i> , "Biochemical characterization of two isoforms of FLT4, a VEGF receptor-related tyrosine kinase," <i>Oncogene</i> 10:973-984, Stockton Press (March 1995)	
	NPL13	Capogrossi, M.C., "Gene Therapy of Coronary Artery Disease," Project No. Z01AG00811-01, Abstract (January 1994)	
	NPL14	Capogrossi, M.C., "Gene Therapy of Coronary Artery Disease," Project No. Z01AG00811-02, Abstract (January 1995)	
	NPL15	Choi, I.H., <i>et al.</i> , "Angiogenesis and Mineralization During Distraction Osteogenesis," <i>J. Korean Med. Sci.</i> 17:435-447, The Korean Academy of Medical Sciences (August 2002)	
	NPL16	Copy of Declaration of Dr. Karl Alitalo, In re of : U.S. Application No. 08/585,895, Alitalo <i>et al.</i> , filed January 12, 1996, submitted November 26, 1997	
	NPL17	Dias, S., <i>et al.</i> , "Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy," <i>Blood</i> 99:2179-2184, The American Society of Hematology (March 2002)	
	NPL18	English language abstract of JP 64-38100A, cited as document FP2 on Form PTO/SB/08A, Derwent Accession No. 1989-088700/198912	
	NPL19	English language abstract of JP 2-117698 A, cited as document FP3 on Form PTO/SB/08A, Derwent Accession No. 1990-181364/199024	
	NPL20	Fan, T.-P., <i>et al.</i> , "Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy," <i>Trends Pharmacol. Sci.</i> 16:57-66, Elsevier Science Ltd. (February 1995)	
✓	NPL21	Isner, J.M., <i>et al.</i> , "Arterial Gene Therapy for Therapeutic Angiogenesis in Patients With Peripheral Artery Disease," <i>Circulation</i> 91:2687-2692, American Heart Association, Inc. (June 1995)	

Examiner Signature	/Celine Qian/	Date Considered	
--------------------	---------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/PTO		Complete if Known	
NINTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/921,143
		Filing Date	August 3, 2001
		First Named Inventor	Coleman, Timothy A.
		Art Unit	1636
		Examiner Name	Qian, Celine X.
		Attorney Docket Number	1488.100000N/HCC/PAC
Sheet	3	of	5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
CQ	NPL22	Isner, J.M., <i>et al.</i> , "Gene therapy for arterial disease," <i>Lancet</i> 344:1653-1654, The Lancet Ltd. (December 1994)	
	NPL23	Isner, J.M., <i>et al.</i> , "Physiologic Assessment of Angiogenesis by Arterial Gene Therapy with Vascular Endothelial Growth," <i>J. Cell. Biochem. (Suppl. 21A)</i> :378, Abstract C6-215, Wiley-Liss (March-April 1995)	
	NPL24	Isner, J.M., <i>et al.</i> , "Therapeutic Angiogenesis in Vascular Medicine," Project No. R01 HL5335401, Abstract (March 1995)	
	NPL25	Kubo, H., <i>et al.</i> , "Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblasts growth factor-2-induced lymphangiogenesis in mouse cornea," <i>Proc. Natl. Acad. Sci.</i> 99:8868-8873, The National Academy of Sciences (June 2002)	
	NPL26	Kuzuya, M. and Kinsella, J.L., "Induction of Endothelial Cell differentiation In Vitro by Fibroblast-Derived Soluble Factors," <i>Exp. Cell Res.</i> 215:310-318, Academic Press, Inc. (December 1994)	
	NPL27	Maher, P.A., "Stimulation of Endothelial Cell Proliferation by Vanadate Is Specific for Microvascular Endothelial Cells," <i>J. Cell. Physiol.</i> 151:549-554, Wiley-Liss, Inc. (1992)	
	NPL28	Maynard, J. and Georgiou, G., "Antibody Engineering," <i>Annu. Rev. Biomed. Eng.</i> 2:339-376, Annual Reviews (August 2000)	
	NPL29	Mesri, E.A., <i>et al.</i> , "Expression of Vascular Endothelial Growth Factor From a Defective Herpes Simplex Virus Type I Amplicon Vector Induces Angiogenesis in Mice," <i>Circulation Res.</i> 76:161-167, American Heart Association, Inc. (February 1995)	
	NPL30	Morea, V., <i>et al.</i> , "Antibody Modeling: Implications for Engineering and Design," <i>Methods</i> 20:267-279, Academic Press (March 2000)	
✓	NPL31	Mülhauser, J., <i>et al.</i> , "In Vivo Gene Transfer into Porcine Cardiac Cells with a Replication-Deficient Recombinant Adenovirus Vector," <i>Circulation</i> 88:1-475, Abstract No. 2558, American Heart Association (October 1993)	

NON PATENT LITERATURE DOCUMENTS

Examiner Signature	/Celine Qian/	Date Considered	
--------------------	---------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
NINTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/921,143
		Filing Date	August 3, 2001
		First Named Inventor	Coleman, Timothy A.
		Art Unit	1636
		Examiner Name	Qian, Celine X.
		Attorney Docket Number	1488.100000N/HCC/PAC
Sheet	4	of	5
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
CQ	NPL32	Mülhauser, J., <i>et al.</i> , "VEGF ₁₆₅ Expressed by a Replication-Deficient Recombinant Adenovirus Vector Induces Angiogenesis In Vivo," <i>Circulation Res.</i> 77:1077-1086, American Heart Association, Inc (December 1995)	
	NPL33	Oikawa, T., <i>et al.</i> , "Three Isoforms of Platelet-Derived Growth Factors All Have the Capacity to Induce Angiogenesis In Vivo," <i>Biol. Pharm. Bull.</i> 17:1686-1688, Pharmaceutical Society of Japan (December 1994)	
	NPL34	Pajusola, K., <i>et al.</i> , "Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors," <i>Oncogene</i> 9:3545-3555, Stockton Press Ltd. (December 1994)	
	NPL35	Pepper, M.S., <i>et al.</i> , "In Vitro Angiogenic and Proteolytic Properties of Bovine Lymphatic Endothelial Cells," <i>Exp. Cell Res.</i> 210:298-305, Academic Press, Inc. (February 1994)	
	NPL36	Plate, K.H., "From angiogenesis to lymphangiogenesis," <i>Nat. Med.</i> 7:151-152, Nature America, Inc. (February 2001)	
	NPL37	Spranger, J. and Pfeiffer, A.F.H., "New concepts in pathogenesis and treatment of diabetic retinopathy," <i>Exp. Clin. Endocrinol. Diabetes</i> 109(Suppl. 2):S438-S450, J.A. Barth Verlag (2001)	
	NPL38	Stacker, S.A. and Achen, M.G., "The Vascular Endothelial Growth Factor Family: Signalling for Vascular Development," <i>Growth Factors</i> 17:1-11, Taylor & Francis (1999)	
	NPL39	Symes, J.F., <i>et al.</i> , "Angiogenesis: potential therapy for ischaemic disease," <i>Curr. Opin. Lipidol.</i> 5:305-312, Current Science Ltd. (August 1994)	
	NPL40	Takeshita, S., <i>et al.</i> , "In Vivo Evidence of Enhanced Angiogenesis Following Direct Arterial Gene Transfer of the Plasmid Encoding Vascular Endothelial Growth Factor," <i>Circulation</i> 88, Abstract No. 2565, American Heart Association, Inc. (October 1993)	
	NPL41	Takeshita, S., <i>et al.</i> , "Therapeutic Angiogenesis. A Single Intraarterial Bolus of Vascular Endothelial Growth Factor Augments Revascularization in a Rabbit Ischemic Hind Limb Model," <i>J. Clin. Invest.</i> 93:662-670, The American Society for Clinical Investigation, Inc. (February 1994)	
↓	NPL42	Vale, P.R., <i>et al.</i> , "Percutaneous Electromechanical Mapping Demonstrates Efficacy of pVGL1 (VEGF2) in an Animal Model of Chronic Myocardial Ischemia," <i>Circulation (Suppl 1.)</i> 100:1-22, Lipponcott Williams & Wilkins (November 1999)	

Examiner Signature	/Celine Qian/	Date Considered	
-----------------------	---------------	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

01/E IAP34
APR 21 2005
PATENT

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
NINTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/921,143
		Filing Date	August 3, 2001
		First Named Inventor	Coleman, Timothy A.
		Art Unit	1636
		Examiner Name	Qian, Celine X.
		Attorney Docket Number	1488.100000N/HCC/PAC
Sheet	5	of	5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ^a	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
CQ	NPL43	Verma, I. and Somia, N., "Gene therapy - promises, problems and prospects," <i>Nature</i> 389:239-242, Macmillan Magazines Ltd. (September 1997)	
	NPL44	Walsh, D.A. and Pearson, C.I., "Angiogenesis in the pathogenesis of inflammatory joint and lung diseases," <i>Arthritis Res.</i> 3:147-153, BioMed Central Ltd. (February 2001)	
	NPL45	Williams, R.S., "Southwestern Internal Medicine Conference: Prospects for Gene Therapy of Ischemic Heart Disease," <i>Am. J. Med. Sci.</i> 306:129-136, Lippincott Williams & Wilkins (August 1993)	
	NPL46	Witzenbichler, B., et al., "Vascular Endothelial Growth Factor-C (VEGF-C/VEGF-2) Promotes Angiogenesis in the Setting of Tissue Ischemia," <i>Am. J. Pathol.</i> 153:381-394, American Society for Investigative Pathology, Inc. (August 1998)	
	NPL47	Yeung, P.K.F., "VEGF-2 St Elizabeth's Medical Center," <i>Curr. Opin. Invest. Drugs</i> 2:796-8000, PharmaPress Ltd. (June 2001)	
	NPL48	Letter from John J. Chicca II, Ph.D., Molecular Diagnostic Services, Inc. regarding a third progress report for a project entitled "Cloning and expression of VEGF-2 gene and the efficacy of VEGF-2 protein utilizing the 3-D collagen angiogenesis assay and proliferation," dated February 16, 2006.	
✓	NPL49	Letter from John J. Chicca II, Ph.D., Molecular Diagnostic Services, Inc. regarding a fourth progress report for a project entitled "Cloning and expression of VEGF-2 protein utilizing the 3-D collagen angiogenesis assay and proliferation," dated march 14, 2006.	

504074_1.DOC

Examiner Signature	Celine Qian	Date Considered	
--------------------	-------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.